Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia

NCT01323374 is registered in ClinicalTrials.gov with Chelsea Therapeutics as lead sponsor.

NCT NCT01323374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01323374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia
Lead sponsor
Chelsea Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
October 31, 2011
Enrollment
122 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia